FindTrial
Sign In

LCZ696 (sacubitril/valsartan)

DRUG5 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Myocardial InfarctionChronic Heart Failure With Reduced Ejection FractionHeart FailureHeart Failure and Reduced Ejection FractionHearth Failure With Reduced Ejection Fraction (HFrEF)

Phase 3

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
CompletedNCT02900378
Novartis PharmaceuticalsChronic Heart Failure With Reduced Ejection Fraction
Start: 2016-12-20End: 2018-04-11Updated: 2020-09-02
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
CompletedNCT02924727
Novartis PharmaceuticalsAcute Myocardial Infarction
Start: 2016-12-09End: 2021-02-26Updated: 2023-06-22

Phase 4

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
CompletedNCT02690974
Novartis PharmaceuticalsHearth Failure With Reduced Ejection Fraction (HFrEF)
Start: 2016-03-08End: 2017-11-29Updated: 2019-06-07
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
CompletedNCT02874794
Novartis PharmaceuticalsHeart Failure and Reduced Ejection Fraction
Start: 2016-08-17End: 2019-01-26Updated: 2021-01-05
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
CompletedNCT02887183
Novartis PharmaceuticalsHeart Failure
Start: 2016-10-25End: 2018-10-22Updated: 2021-10-07

Related Papers

Changes in cardiac structure and function are associated with health‐related quality of life in heart failure patients with reduced ejection fraction: Results from the <scp>EVALUATE</scp> ‐ <scp>HF</scp> trial
European Journal of Heart Failure2025-07-181 citations
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.
2024-10-016 citations
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
2024-03-0111 citations
Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI
Journal of the American Heart Association2023-08-2313 citations
Changes in Mid-Regional Pro-Adrenomedullin During Treatment with Sacubitril/Valsartan
European Journal of Heart Failure2023-07-047 citations
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Circulation Heart Failure2023-05-0142 citations
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan
JACC Heart Failure2022-11-0916 citations
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
Circulation2022-11-0227 citations
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy
Circulation2022-10-0356 citations
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
2022-10-0138 citations
Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study
Clinical Chemistry2022-09-144 citations
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status
JACC Heart Failure2022-09-0716 citations
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: <scp>the EVALUATE‐HF trial</scp>
European Journal of Heart Failure2022-05-1320 citations
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan
JACC Heart Failure2022-01-1223 citations
Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
New England Journal of Medicine2021-11-10274 citations
Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction
Circulation Heart Failure2021-05-1538 citations
Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study
Circulation Heart Failure2021-03-0112 citations
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
JACC Heart Failure2020-12-0948 citations
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
JACC Heart Failure2020-11-1185 citations
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction
JACC Heart Failure2020-11-1131 citations

5 more papers not shown